
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
IGF-1 LR3 (UPA Platinum)
|
Category: |
Muscle / GH / Performance |
|
SKU: |
TRW-IGF1LR3 |
|
Price: |
R 490.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS IGF-1 LR3 100 | IGF-1 LR3 100mcg Self-Mix Vial
IGF-1 LR3 100 (IGF-1 LR3 100mcg) – Long-acting Insulin-Like Growth Factor-1 analogue for muscle hyperplasia, enhanced nutrient delivery, and accelerated tissue repair. Extended 20–30 hour half-life. Includes 2ml Bacteriostatic water.
Product Overview
IGF-1 LR3 100 is an IGF-1 LR3 100mcg self-mix vial. IGF-1 LR3 (Long Arginine 3-IGF-1) is a synthetic analogue of human insulin-like growth factor-1 (IGF-1) engineered with two key structural modifications: an arginine substitution for glutamic acid at position 3 of the amino acid sequence, and a 13-amino-acid N-terminal extension (MFPAMPLLSLFVN).
These modifications yield a peptide of 83 amino acids — 13 more than native IGF-1's 70 — with a dramatically extended half-life of approximately 20–30 hours, compared to native IGF-1's half-life of only 12–15 minutes when unbound.
The extended half-life enables once-daily dosing and produces a sustained anabolic signal at the IGF-1 receptor.
How IGF-1 LR3 Works: IGF-1 Receptor Agonist Pathway
IGF-1 LR3 binds to the type 1 IGF receptor (IGF-1R) with affinity similar to wild-type IGF-1. Upon binding, the receptor's intrinsic tyrosine kinase activity is activated, leading to autophosphorylation of tyrosine residues on the β-subunit.
This activation triggers a cascade of intracellular signaling events that promote cell survival, proliferation, and differentiation. IGF-1 LR3 is approximately three times more potent than native IGF-1 in stimulating the type I IGF receptor, inducing a higher level of activation of intracellular signaling molecules responsible for promoting cell survival by inhibition of apoptosis.
The critical distinction from native IGF-1 lies in its binding protein interaction. Native IGF-1 is rapidly sequestered and deactivated by IGF-binding proteins (IGFBPs) within minutes of entering circulation. The LR3 modifications — particularly the arginine substitution at position 3 — result in very low affinity for IGFBPs.
Without IGFBP interference, IGF-1 LR3 remains active in circulation for 20–30 hours: nearly 100 times longer than natural IGF-1. This means a single daily injection provides sustained IGF-1 receptor activation, driving anabolic signaling throughout the day.
Body Recomposition Benefits
IGF-1 LR3 promotes favourable body composition changes through multiple mechanisms. It stimulates muscle protein synthesis, enhances nutrient uptake into muscle cells, and inhibits muscle protein breakdown.
More significantly, IGF-1 LR3 has been shown in preclinical models to stimulate muscle hyperplasia — the creation of new muscle cells (myocytes) — rather than merely hypertrophy (enlargement of existing cells).
This is a unique property that most anabolic compounds lack. In animal studies, IGF peptides stimulated the growth of normal growing animals, with IGF-I variants that bind less well to IGF-binding proteins being more active than native IGF-I.
Preclinical research indicates that IGF-1 LR3 causes localized IGF levels to rise dramatically at the site of injection, promoting muscle cell proliferation in the targeted tissue.
Clinical data and user logs suggest a potential increase in lean body mass of 5–10% over a successful cycle, though these figures derive from anecdotal reports rather than controlled human trials.
The hyperplasia effect is often described as an "investment in future potential" — new muscle fibers created during a cycle provide a permanent foundation for future growth.
Beyond muscle effects, IGF-1 LR3 enhances nutrient delivery to muscle tissue and accelerates recovery from training-induced damage. This makes it particularly valuable in body recomposition protocols where simultaneous fat loss and muscle preservation are the objectives.
Titration Protocol
IGF-1 LR3 is administered via subcutaneous or intramuscular injection. The optimal dosage range for most users falls between 20–50 mcg per day, with the "golden rule" being to start low and slow.
Clinical protocols typically run 20–80 mcg daily, with cycle lengths held to 4–6 weeks due to receptor downregulation concerns, followed by an equal or longer washout period.
A standard titration schedule is as follows:
· Week 1–2 (Ramp-up): 20–30 mcg once daily — establishes baseline tolerability and assesses hypoglycemia risk
· Week 3–4 (Build): 30–40 mcg once daily — standard working dose; may be increased by 10–20 mcg weekly based on response
· Week 5–6 (Peak): 40–50 mcg once daily — advanced range for experienced users; some protocols split into two daily doses
· Cycle completion: 4–6 weeks on, followed by 3–6 weeks off between cycles
Injection timing matters significantly. Post-workout administration capitalizes on exercise-induced growth hormone release, while pre-bed injection aligns with the body's natural nocturnal GH pulse.
Injections should be administered with carbohydrates on board — IGF-1 LR3 carries significant hypoglycemia risk, with reported incidence of >40% in some protocols. Blood glucose should be monitored throughout the cycle, particularly during the first two weeks of titration.
Combination Therapy
IGF-1 LR3 is commonly used as part of broader wellness and body recomposition protocols:
· Growth hormone secretagogues (CJC-1295 / Ipamorelin): IGF-1 LR3 represents the downstream anabolic signal of growth hormone. Stacking with CJC-1295/Ipamorelin provides upstream GH stimulation alongside downstream IGF-1 receptor activation.
Research-community protocols typically run IGF-1 LR3 at 50 mcg post-workout alongside CJC-1295/Ipamorelin at 250 mcg, using a 5 days on / 2 days off schedule to give the pituitary a breather.
· PEG-MGF: The "Recovery" stack combines IGF-1 LR3 with pegylated mechano growth factor. IGF-1 LR3 supports protein synthesis and inhibits catabolism, while PEG-MGF activates satellite cell recruitment — a crucial component of true hypertrophy. Without new myonuclei, muscle fibers can only enlarge so far. This combination supports expansion of cellular capacity.
· AOD-9604: The "Cutting" stack pairs IGF-1 LR3 with AOD-9604 (hGH fragment 176–191). IGF-1 LR3 drives anabolic signaling and muscle preservation, while AOD-9604 promotes targeted lipolysis without affecting lean mass. This combination is designed for body recomposition — building muscle while stripping fat.
· Retatrutide + MOTS-c: Community-reported protocols describe a "Recomp Formula" combining IGF-1 LR3 as the "kingpin" for muscle building, retatrutide as the primary fat-loss tool, and MOTS-c for mitochondrial AMPK activation.
This triple stack targets all three pillars of body recomposition: muscle growth, fat loss, and metabolic optimisation.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
IGF-1 LR3 has never been evaluated in a human clinical trial. No pharmacokinetic, pharmacodynamic, tolerability, or safety data exist in humans.
The actual adverse effect profile, drug interactions, and long-term consequences of exposure are entirely unknown. A 2026 review in Frontiers in Endocrinology stratifying performance-enhancing peptides by evidence tier classified IGF-1 LR3 among compounds with a complete absence of human studies.
The closest human safety data belongs to a different molecule: recombinant human IGF-1 (mecasermin, Increlex), studied in children with severe growth disorders.
In a European registry of 195 treated children, the most frequent targeted treatment-emergent adverse events were hypoglycemia (17.6%), lipohypertrophy (10.6%), tonsillar hypertrophy (7.4%), injection site reactions (6.4%), and headache (5.9%).
Mecasermin is FDA-approved for severe primary IGF-1 deficiency but is not the same molecule as IGF-1 LR3 — LR3 binds IGF binding proteins poorly, which is precisely why borrowing mecasermin's safety numbers is unreliable in both directions.
All identified studies on IGF-1 LR3 have been preclinical, including successful recombinant protein expression in yeast and mixed results in animal models.
Animal work on LR3 itself found suppressed insulin secretion in fetal sheep and suppressed growth hormone in pigs. No quantified human LR3 efficacy estimate exists — only consistent anecdotal localized-growth and recovery reports.
Technical Specifications
· Product Name: IGF-1 LR3 100
· Peptide: IGF-1 LR3 (Long Arginine 3-IGF-1, 83 amino acids)
· Concentration: 100mcg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Half-life: Approximately 20–30 hours
· Administration: Subcutaneous or intramuscular injection, once daily
· Storage: Lyophilized powder at -20°C to -80°C; reconstituted solution at 2–8°C, use within 1 week
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. PEG-MGF 5000 is intended for use under professional medical supervision.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.